Beryl Drugs Limited has completed the filing of its quarterly compliance reports with the Bombay Stock Exchange for the quarter ended March 31, 2026. The pharmaceutical company submitted the required documentation on April 6, 2026, ensuring adherence to various regulatory obligations under the Securities and Exchange Board of India framework.

Compliance Reports Filed

The company filed three essential compliance certificates as mandated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Depositories Compliance Confirmation

Adroit Corporate Services Private Limited, serving as the company's Registrar and Share Transfer Agent, provided detailed confirmation regarding dematerialisation activities during the quarter. The agent confirmed that all securities received from depository participants for dematerialisation were properly processed and confirmed to the depositories within the stipulated timeframe.

The compliance certificate specifically states that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories were substituted in the register of members as registered owners within the mandatory 15-day period.

Non-Applicability Declaration

In the official filing, Beryl Drugs confirmed that Regulation 57(5) is not applicable to the company since there are no non-convertible securities for which interest, dividend, or principal is payable during the quarter ended March 31, 2026. This declaration was made in accordance with SEBI compliance requirements for listed companies.

Share Transfer Facility Maintenance

Under Regulation 7(3) of the SEBI LODR Regulations, Beryl Drugs confirmed that activities related to both physical and electronic share transfer facilities were maintained throughout the period from April 01, 2025 to March 31, 2026. The company's share transfer operations are managed by Adroit Corporate Services Private Limited.

Corporate Information

The timely filing of these compliance reports demonstrates Beryl Drugs' commitment to maintaining regulatory standards and transparency in its operations as a publicly listed pharmaceutical company.

Beryl Drugs Limited has officially confirmed the completion of dispatch for its Extraordinary General Meeting (EOGM) notice to eligible shareholders. The company filed a notification with BSE on April 3, 2026, confirming that newspaper advertisements have been published to notify shareholders about the completion of notice dispatch along with e-voting information and record date details.

EOGM Schedule and Voting Framework

The EOGM is scheduled for Monday, May 11, 2026, at 11:00 AM at Kanchan Palace, Community Hall, Nipania Ring Road, Indore (M.P.). The company has established a comprehensive remote e-voting framework under Section 108 of the Companies Act, 2013, providing shareholders with electronic voting facilities.

Shareholders holding shares in either physical or dematerialized form as on the cut-off date of May 4, 2026, will be entitled to participate in remote e-voting or vote at the EOGM venue.

Key Agenda Items and Director Appointments

The EOGM will address three special business items focusing on director appointments and corporate governance matters. The meeting will regularize Mr. Shailendra Pathak's appointment as Whole Time Director, who was initially appointed as Additional Director on January 3, 2026.

Mrs. Neha Sarda will be appointed as Non-Executive Independent Director, bringing her expertise as a qualified Company Secretary with over 8 years of experience in corporate compliance and Company Law matters.

Related Party Transaction Approval

The EOGM will seek approval for material Related Party Transactions with M/s. Aminova Infusions P. Ltd., where Mr. Shailendra Pathak serves as a director holding 50% equity. This transaction requires shareholder approval as it represents approximately 13.30% of the company's annual consolidated turnover.

The transaction involves Aminova distributing Beryl Drugs' PP Bottle and FFS products in Maharashtra, Gujarat, and international markets, leveraging Mr. Pathak's pharmaceutical industry expertise.

Regulatory Compliance and Communication

The company's latest BSE filing demonstrates its commitment to maintaining transparent communication with stakeholders. Managing Director Sanjay Sethi (DIN: 00090277) signed the official notification confirming the completion of notice dispatch through newspaper advertisements.

The e-voting results will be announced after the EOGM, with the Scrutinizer's Report being placed on the company's website. The comprehensive regulatory compliance framework ensures all shareholders can participate effectively in the decision-making process while strengthening corporate governance standards.